✨ Free AI Report
Kamada Ltd.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Kamada Ltd.
Company Research

Kamada Ltd.: Business Overview, Financials & Competitive Analysis

Kamada Ltd. scores 7/10 on the AskCyborg Cyborg Score (Strong). Growing specialty plasma player with proven commercial traction, profitable operations, and diversified pipeline offering defensive growth in niche therapeutic markets. Kamada demonstrates solid fundamentals with FDA-approved products generating commercial revenue, profitability growth (35% EBITDA increase YoY in 9M 2025), and clear strategic pillars for expansion. The company faces geopolitical risks.

What is Kamada Ltd.'s industry? Kamada Ltd. (kamada.com) operates in Biopharmaceuticals - Specialty Plasma-Derived Therapeutics. AskCyborg classifies Kamada Ltd. under Biopharmaceuticals - Specialty Plasma-Derived Therapeutics in its company registry.

Kamada is a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, with a diverse portfolio of marketed products, a robust development pipeline and industry-leading m...

7/ 10Strong

Cyborg Score thesis

Growing specialty plasma player with proven commercial traction, profitable operations, and diversified pipeline offering...

Read the full analyst-debate transcript →
Industry Biopharmaceuticals - Specialty Plasma-Derived Therapeutics
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Kamada Ltd. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Kamada Ltd.

AskCyborg analysts argue the bull and bear cases for Kamada Ltd. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Kamada Ltd. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Kamada Ltd. Overview

Pro stress-test →

Kamada is a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, with a diverse portfolio of marketed products, a robust development pipeline and industry-leading manufacturing capabilities. The company serves patients with rare and serious conditions through FDA-approved products and strategic distribution partnerships across 30+ countries.

Strategic Profile

Pro stress-test →

The company's strategy focuses on driving profitable growth through four primary pillars: organic growth from commercial activities including six FDA-approved specialty plasma-derived products (KEDRAB, CYTOGAM, GLASSIA, WINRHO SDF, VARIZIG, HEPAGAM B), new business development and M&A opportunities, plasma collection expansion, and development of additional product candidates. Kamada balances commercial stage profitability with innovative pipeline advancement in specialty plasma therapeutics.

Competitive Landscape

Pro stress-test →

Kamada competes in the specialty plasma-derived therapeutics market against larger pharma companies that develop immunoglobulins and plasma products. Takeda holds manufacturing and distribution rights for Glassia in major markets (US, Canada, Australia, New Zealand) with Kamada receiving royalties, while Kamada maintains direct distribution and partnerships globally for its portfolio.

Industry Context

Kamada Ltd. operates in Biopharmaceuticals - Specialty Plasma-Derived Therapeutics.

Key facts

Founded: 1990 · Headquarters: Rehovot, Israel (with operations in Hoboken, NJ) · Revenue: $135.8M (9M 2025)

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Kamada Ltd..

  • Nine-month 2025 revenue reached $135.8 million, up 11% YoY with adjusted EBITDA of $34.2 million, up 35% YoY, supporting full-year revenue guidance of $178 million
  • The company is expanding plasma collection operations with three operating centers in the United States (Beaumont, Houston, San Antonio, Texas) to support revenue growth through plasma sales and hyper-immune plasma demand
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • March 2025Obtained tax ruling from Israel Tax Authority enabling reduced withholding tax rates for international shareholders on special dividend distributions
  • November 2025Initiated post-marketing study evaluating CYTOGAM's role in reducing late CMV disease risk in high-risk kidney transplant recipients
  • +1 moreTrack every material event for Kamada Ltd. as it happens. Explore monitoring →
Get alerted when Kamada Ltd. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Glassia (AAT therapy)Licensed from Kamada for US/major markets distribution→Immunoglobulin therapiesPlasma-derived immunoglobulin competitor→Specialty plasma productsGlobal plasma therapeutics company→

Compare Kamada Ltd. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Kamada Ltd. operates in Biopharmaceuticals - Specialty Plasma-Derived Therapeutics. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceuticals - Specialty Plasma-Derived Therapeutics research →
NEW · MCP server

Ask your AI assistant about Kamada Ltd.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Kamada Ltd. and its top competitor on Cyborg Score”
“What did Kamada Ltd. do this quarter?”
“Is Kamada Ltd. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Kamada Ltd. do?+
Kamada is a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, with a diverse portfolio of marketed products, a robust development pipeline and industry-leading m...
What is Kamada Ltd.'s Cyborg Score?+
Kamada Ltd. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Kamada Ltd.'s main competitors?+
Named competitors include Glassia (AAT therapy), Immunoglobulin therapies, Specialty plasma products. The full competitive landscape is in the AskCyborg report.
How can I get the full Kamada Ltd. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Kamada Ltd. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Kamada Ltd. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.